Prospective Evaluation of Treatment Success in Patients with REM Sleep Behavior Disorder Using Melatonin

Prospective Evaluation of Treatment Success in Patients with REM Sleep Behavior Disorder Using Melatonin - PEBMPR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023534

Enrollment

300

Registered

2020-11-10

Start date

2019-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G25.88 G20.00

Interventions

Group 1: Circadin (melatonin), 2 mg/day p.o. (tablet), for at least 6 months Group 2: mixed therapy

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: REM sleep behavior disorder

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
conversion to clinical synucleinopathy	—

Secondary

Measure	Time frame
cognition, neuromotor performance, neurovegetative evaluation, olfaction, sleep-related symptoms	—

Countries

Germany

Contacts

Public ContactDieter Kunz

St. Hedwig-Krankenhaus

dieter.kunz@charite.de0049-30-23112900

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026